Amarin Corp Plc (AMRN)

[ziploc_1]

The S.C. justices are aware that 'skinny labels" award the generics with an opportunity to reap profits by skirting patent law...and they weaken innovation, as even the solicitor general must be aware...I would not be surprised if the S.C. refuses to take this new suit...A reversal would not be good for the public's interest in the short term by making branded drugs more expensive...and, in the long term, by making new innovative branded drugs less available.

I think most of us understand that the "skinny label" is really a loophole in the HW law, being taken advantage of by generic companies.